What's happening
This bill requires the New York health commissioner to create regulations promoting opioid recovery and reducing diversion of addiction medications.
Why it matters
Ensures patients receive full information and choice. The bill mandates that all patients seeking treatment for opioid use disorder must be educated about all FDA-approved addiction medication options, and their informed choice must be documented, helping patients make better-informed decisions and potentially improving treatment outcomes.
Promotes comprehensive, individualized care. It requires treatment plans to be tailored and regularly reviewed, use of standardized assessment tools to determine care levels, and inclusion of counseling and peer recovery support, encouraging a holistic approach to recovery rather than a one-size-fits-all model.
Reduces risk of medication misuse and diversion. By implementing diversion control practices—such as limiting initial prescriptions, requiring toxicology screenings, and monitoring for compliance—the bill aims to prevent addiction medications from being misused or sold illegally, balancing access with public safety.
Increases accountability for providers. The legislation establishes monitoring and penalties for non-compliance, ensuring that medical providers adhere to best practices and new state standards, which may improve quality of care and patient safety across opioid treatment programs.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Who cares
Headline styles
Limit Addiction Medicine Misuse
Plain English, a few words. Used as the page title.
Sponsors
No co-sponsors yet.
History
- Referred to alcoholism and substance abuse
- Referred to alcoholism and substance abuse
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
3317
2019-2020 Regular Sessions
IN SENATE
February 5, 2019
Introduced by Sen. LANZA -- read twice and ordered printed, and when printed to be committed to the Committee on Alcoholism and Substance Abuse
AN ACT to amend the public health law, in relation to directing the commissioner of the department of health to promulgate rules and regulations promoting recovery from opioid abuse and reducing diversion of addiction medicines
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. The public health law is amended by adding a new section 3309-b to read as follows:
§ 3309-b. Promoting recovery from opioid abuse and reducing diversion of addiction medicines. 1. The commissioner shall, in consultation with the office of alcoholism and substance abuse services, promulgate rules and regulations pertaining to individual physicians and group practices including, but not limited to, physician's office-based opioid treatment, opioid treatment programs and any other treatment practices serving more than fifty patients at a time who have a primary or secondary diagnosis of opiate misuse or addiction. Such rules and regulations shall at a minimum include the following provisions:
(a) All patients seeking treatment for opiate use disorder shall be given an orientation including factual information and an easily understood explanation of each addiction medication option approved by the United States food and drug administration. Such education must be documented in the patient record along with documentation regarding the patient's choice of one of the medication options or none of them. Such documentation shall be signed by the patient, or the commissioner may specify some other form of documentation showing that the medical provider made a good faith effort to obtain such informed consent from the patient;
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD08208-01-9
S. 3317 2
(b) If a patient chooses an addiction medication not available through the medical practitioner, such practitioner must make a referral to a treatment setting where the patient can access his or her preferred medication option;
(c) The medical provider shall utilize the level of care for alcohol and drug treatment referral web application provided by the office of alcoholism and substance abuse services or another patient assessment instrument approved by the office of alcoholism and substance abuse services to help determine an appropriate level of patient care;
(d) In the event that the patient using opiates declines to engage in treatment the medical provider shall provide such patient with information about accessible harm reduction services;
(e) Treatment counseling shall be provided to all individuals for whom an addiction medication is prescribed or dispensed. Such treatment counseling may be provided by a qualified addiction professional, as determined by the office of alcoholism and substance abuse services, employed by the medical practice or through a contract with an office of alcoholism and substance abuse services certified treatment program;
(f) The medical provider shall develop a treatment plan for each patient and such plan shall be reviewed, at a minimum, every six months. The standards for developing individual treatment plans shall be determined by the office of alcoholism and substance abuse services and shall be consistent with the standards used in other office of alcoholism and substance abuse services licensed outpatient treatment programs;
(g) The medical provider shall inform patients about available peer recovery support services; and
(h) When an addiction medication is not taken under direct clinical supervision, the medical provider shall utilize diversion control practices to ensure such medication is taken as prescribed and not diverted. Such practices shall be determined by the commissioner and shall include:
(i) limits on the amount of medication prescribed and the number of refills given to a patient until such patient has established a pattern of reliability; and
(ii) minimum toxicology screening standards.
2. For all medical providers subject to these rules and regulations, the commissioner shall ensure that providers are monitored for compliance. Such monitoring shall be done directly by the department or by an independent organization specified by the commissioner.
3. The commissioner shall establish appropriate penalties for medical practitioners who fail to comply with such rules and regulations promulgated under subdivision one of this section.
§ 2. This act shall take effect January 1, 2020. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Sponsor's memo
Title of bill
An act to amend the public health law, in relation to directing the commissioner of the department of health to promulgate rules and regu- lations promoting recovery from opioid abuse and reducing diversion of addiction medicines
Purpose or general idea of bill
Directs the New York State Health Commissioner to promulgate rules and regulation to reduce the diversion of addiction medications.
Summary of provisions
Section 1. This section amends the Public Health law by adding a new section, 3309-b to promote recovery from opioid abuse and reduce the diversion of addiction medicines.
Section 2. This section provides the effective date.
Justification
The opioid epidemic has created the need to expand the availability of treatment for persons with substance use disorders. The Comprehensive Addiction Recovery Act enacted by Congress in 2016 includes a provision that permits individual and group medical practices to increase the number of patients they can treat with Buprenorphine products to 275 to address opioid addiction. With this expansion of treatment, it is imper- ative to implement quality standards that assure evidence-based clinical practice and proper safeguards to reduce diversion and risk for relapse.
This legislation aims to establish clinical standards for these medial practices that include evidence-based treatment protocols recommended by the New York State Office of Alcoholism and Substance Abuse Services.
Prior legislative history
2018: S.6815A - Referred to Health / A.8566A - Referred to Alcoholism & Drug Abuse 2017: S.6815 - Referred to Rules / A.8566 - Referred to Alcoholism & Drug Abuse
Fiscal implications for state and local governments
None.
Effective date
This act shall take effect January 1, 2019; provided, however, that effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effec- tive date are authorized to be made and completed on or before such effective date.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.